Essity Q2 profit beats on Health volumes despite Consumer Tissue weakness

Essity reported Q2 adjusted operating profit (EBITA) of 4.69B crowns, slightly above the 4.6B LSEG forecast, but profit fell 12% to 2.69B and EPS dropped to 3.94 crowns from 4.39. Organic sales rose only 0.3% (vs 1.9% a year earlier), with Consumer Tissue organic sales down 5.3% and EBITA margin in that segment falling to 9.7% from 11.7% on higher distribution/energy costs and lower volumes. Essity also started a new 3B crown share buyback program on May 12 as it works to secure profitable volumes and improve pricing.

Analysis

This is a low-quality print beneath the headline: operating momentum is being driven by volume, but the pricing line is still leaking, which means the margin base is more fragile than the near-term EPS beat implies. In staples, that usually precedes either a renewed price push or a prolonged period of under-earning versus peers; in both cases, the key variable is whether management can stabilize the largest category without giving back share.

Competitive dynamics look more interesting than the reported numbers. If Essity tries to restore price in Consumer Tissue, the likely beneficiaries are private-label suppliers and lower-cost rivals with better local manufacturing economics, while branded peers such as KMB and PG can absorb some of the shelf-space disruption with stronger mix and pricing power. If instead Essity protects volume, the margin drag likely persists into the next 1-2 quarters, and the buyback will mainly mask weaker operating leverage rather than fix it.

The contrarian point is that the market may be too willing to treat this as a routine staples beat plus capital return story. A strategic review of the weakest segment is usually a sign that management is preparing for slower structural growth, and that tends to cap the multiple unless there is clear evidence of pricing recovery. This is mostly a 1-3 month revision-risk setup, with 6-18 month downside if Consumer Tissue fails to reprice and the company leans too hard on repurchases to sustain EPS.

Key Decisions for Investors

• Relative value: long KMB / short ETTYF for 1-3 months. Thesis: better brand pricing and U.S. scale should outperform a business still working through price resets and cost leakage. Risk/reward is attractive if Consumer Tissue margins remain under 10-11% and volumes stay soft.
• If you need a cleaner defensive-staples exposure, prefer PG over ETTYF on any European consumer-staples pullback. PG offers better multiple support and less dependence on a single category repair; use ETTYF as the funding short rather than adding outright long exposure here.
• Fade rallies in ETTYF into strength over the next few sessions if the market overweights the buyback. The buyback supports the stock tactically, but unless next-quarter organic growth re-accelerates above low-single digits and pricing turns positive, the operating trend likely reverts lower.
• Set a catalyst alert for the next quarterly update: if Consumer Tissue margin does not recover by at least ~100 bps from current levels or if price/mix stays negative, treat the thesis as broken and cover any short. If margins improve while volume holds, the de-rating risk eases.